Heron Therapeuti (HRTX)vsMerck & Company Inc (MRK)
HRTX
Heron Therapeuti
$0.32
-4.96%
HEALTHCARE · Cap: $92.90M
MRK
Merck & Company Inc
$135.97
+0.10%
HEALTHCARE · Cap: $335.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 44070% more annual revenue ($66.57B vs $150.71M). MRK leads profitability with a 4.8% profit margin vs -20.5%. MRK earns a higher WallStSmart Score of 34/100 (F).
HRTX
Avoid27
out of 100
Grade: F
MRK
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HRTX.
Margin of Safety
-64.9%
Fair Value
$82.46
Current Price
$135.97
$53.51 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -338.6% — below average capital efficiency
Revenue declined 10.8%
Trading at 8.0x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HRTX
HRTX has a balanced fundamental profile.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : HRTX
The primary concerns for HRTX are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 21.48 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 108.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
HRTX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
HRTX carries more volatility with a beta of 1.67 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (34/100 vs 27/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Heron Therapeuti
HEALTHCARE · BIOTECHNOLOGY · USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?